Luvadaxistat
- Generic Name
- Luvadaxistat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C13H11F3N2O2
- CAS Number
- 1425511-32-5
- Unique Ingredient Identifier
- 76IC00YRVR
- Background
Luvadaxistat is under investigation in clinical trial NCT03214588 (Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia).
- Associated Conditions
- -
- Associated Therapies
- -
Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 216
- Registration Number
- NCT05182476
- Locations
- 🇪🇸
Neurocrine Clinical Site, Madrid, Spain
A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of Schizophrenia
- First Posted Date
- 2017-12-26
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 256
- Registration Number
- NCT03382639
- Locations
- 🇺🇸
Semel Institute for Neuroscience and Human Behavior, Los Angeles, California, United States
🇵🇱NZOZ Poradnia Zdrowia Psychicznego, Kobierzyce, Poland
🇵🇱Centrum Medyczne Plejady, Krakow, Poland
A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizophrenia
- First Posted Date
- 2017-12-02
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 31
- Registration Number
- NCT03359785
- Locations
- 🇺🇸
CBH Health, LLC, Gaithersburg, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath